Clinical trial NCT05495802: Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"
Official title: Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Bone Metastases
Keywords: bone localisations of haematological diseases
Cancer
bone metastasis
haematological diseases
quality of life
epidemiological data
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
Collaborators: name: Lille University Hospital Emergence Fund
First posted: 2022-08-10
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients whose file is presented in MM OOSLOH for a diagnostic, therapeutic or follow-up question of a malignant bone lesion

Brief summary: Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap.

Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures.

To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient


Eligibility criteria: Inclusion Criteria:

* Patient aged 18 or over,
* Patient whose file is presented to the OOSLOH MM and who has not objected to the use of his non-nominative clinical, biological and imaging data
* Social insured patient

Exclusion Criteria:

* Patient who died before presentation to OOSLOH MM,
* Minor patient,
* Patient objecting to the use of their data for research purposes,
* Patient unable to express his right to object to his participation in the study.

Primary outcomes:
measure: Percentage of alive patients
timeFrame: through study completion, an average of 10 years
Secondary outcomes:
measure: Percentage of patients without bone disease recurrence
timeFrame: within one year after the multidisciplinary meeting
measure: Time to bone disease recurrence
timeFrame: through study completion, an average of 10 years
measure: Number of bone recurrence Number of bone recurrence
timeFrame: At each presentation of the patient file's to the MM,on average every week
measure: Epidemiological datas
timeFrame: At the first presentation of patient's file to the MM, on average every week
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Lille
name: Marie-Hélène VIEILLARD, MD
role: PRINCIPAL_INVESTIGATOR
References: